Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing precision medicines for genetically defined diseases. Its lead program is bezuclastinib, which the company is advancing for systemic mastocytosis (SM) and gastrointestinal stromal tumor (GIST), alongside earlier-stage kinase inhibitor programs.

14.23

— Cogent Biosciences, Inc.
	%
Lead clinical asset: bezuclastinib	70% A precision-medicine kinase inhibitor being developed for SM and GIST, with potential U.S. and select international commercialization.
Other clinical-stage pipeline	20% Earlier-stage targeted oncology and rare-disease programs including CGT4859, CGT4255, and CGT6297.
Preclinical discovery programs	10% Internal discovery efforts in JAK2, KRAS, and other undisclosed programs intended to expand the pipeline.

Cogent does not currently sell approved products, so its near-term 'customers' are primarily patients, physicians, and...

Clinical trial patients and investigatorsprimary
Patients with SM, GIST, and other genetically driven diseases enrolled in trials, and the physicians/sites running those studies.
Hematology and oncology prescribersprimary
Specialists who would prescribe bezuclastinib after approval because the target diseases are managed in specialty care settings.
Specialty pharmacies and hospitalssecondary
Distribution and dispensing channels for a future commercial launch, especially for rare-disease and oncology drugs.
Third-party commercialization partnerssecondary
Potential collaborators that can provide local market access, sales, and distribution capabilities outside the U.S.

Cogent is headquartered in the United States and currently conducts most of its business there through R&D, clinical...

•United States is the core operating base for R&D and corporate functions
•Future launch focus includes the U.S. for bezuclastinib
•Select international markets may be served through partners
•No product revenue yet, so geography is driven by trial sites and development activity
•Ex-U.S. expansion depends on regulatory approval and local commercialization partners

Cogent's strategy is centered on advancing bezuclastinib through regulatory approval and, if approved, launching it in...

Regulatory approval and launch of bezuclastinibshort-term

This is the lead asset and the main path to first product revenue and value creation.

Pipeline expansion beyond bezuclastinibmedium-term

A broader pipeline reduces single-asset dependence and supports longer-term growth.

Partnerships and licensingmedium-term

External partners can provide local market access, development support, and commercialization scale.

Cogent is highly dependent on bezuclastinib, so clinical, regulatory, or commercial setbacks in that program would have...

critical

Bezuclastinib development risk

The company says its business is highly dependent on the success of bezuclastinib and related trials.

Scope: Lead asset for SM and GIST
Materiality: high

high

Financing and dilution risk

Cogent has no product revenue and expects to fund operations through equity, debt, and collaborations.

Scope: Pre-commercial stage cash burn
Materiality: high

high

Manufacturing and supply-chain concentration

API and drug product for bezuclastinib are sourced from single-source suppliers.

Scope: Clinical supply and future commercial launch
Materiality: high

high

Regulatory and approval risk

Approval depends on successful clinical data and FDA/EMA review outcomes.

Scope: SUMMIT, PEAK, APEX and future filings
Materiality: high

medium

Competitive pressure

Larger pharma and biotech companies may develop safer, more effective, or faster-approved therapies.

Scope: Precision medicine and rare-disease oncology
Materiality: medium

Accrued research and development expenses

Can shift reported R&D expense and net loss between periods

Stock-based compensation valuation

Affects operating expense and equity compensation trends

Going-concern-style funding dependence

Dilution, debt covenants, and financing costs may affect future statements

Clinical development cost capitalization

R&D intensity remains the main driver of losses

Cogent Biosciences, Inc.

Bezuclastinib development risk

Financing and dilution risk

Manufacturing and supply-chain concentration

Regulatory and approval risk

Competitive pressure

Nuvalent, Inc.

PLIANT THERAPEUTICS, INC.

Solid Biosciences Inc.

Sagimet Biosciences Inc.

MUSTANG BIO, INC.

Gain Therapeutics, Inc.